Sign in

CIK 0001501989 · Accelerated filer

CytomX Therapeutics, Inc.

Sign in to watch
Ticker
CTMX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273521219
Phone
650.515.3185
Business address
151 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
  1. SC 13G/A Stake Amended Statement of Ownership
  2. 4 Grant or award CEO acquired 90,000 shares (grant or award)
  3. 4 Grant or award General Counsel acquired 25,000 shares (grant or award)
  4. 4 Grant or award SVP, Finance and Accounting acquired 40,000 shares (grant or award)
  5. 4 Grant or award Chief Business Officer acquired 30,000 shares (grant or award)
  6. 4 Grant or award SVP, Chief Scientific Officer acquired 26,250 shares (grant or award)
  7. 4 Grant or award Chief Medical Officer acquired 26,250 shares (grant or award)
  8. 4 Open-market sale CEO sold 13,551 shares at $1.38 ($18,710)
  9. 4 Open-market sale SVP, Chief Scientific Officer sold 4,077 shares at $1.38 ($5,628)
  10. 4 Open-market sale Chief Business Officer sold 4,077 shares at $1.38 ($5,628)
  11. 4 Open-market sale General Counsel sold 4,077 shares at $1.38 ($5,629)
  12. 4 Open-market sale SVP, Finance and Accounting sold 1,990 shares at $1.38 ($2,747)
  13. 4 Option exercise SVP, Finance and Accounting acquired 6,875 shares (option exercise)
  14. 4 Option exercise CEO acquired 37,500 shares (option exercise)
  15. 4 Option exercise Chief Business Officer acquired 11,250 shares (option exercise)
  16. 4 Option exercise General Counsel acquired 11,250 shares (option exercise)
  17. 4 Option exercise SVP, Chief Scientific Officer acquired 11,250 shares (option exercise)
  18. 8-K Event Results of operations
  19. 10-Q Report Quarterly Report
  20. 4 Open-market sale SVP, Chief Scientific Officer sold 4,119 shares at $1.30 ($5,356)

Page 10 of 41 · 801 filings